Abstract:Background: Cancer-testis genes can serve as prognostic biomarkers and valuable targets for immunotherapy in multiple tumors because of their restricted expression in testis and cancer. However, their expression pattern in hepatocellular carcinoma is still not well understood. The purpose is to comprehensively characterize the cancer-testis gene expression in hepatocellular carcinoma as well as identify prognostic markers and potential targets for immunotherapy. Methods: Cancer-testis database and publicly available data sets reporting new cancer-testis genes were integrated, and then restricted them in a testis and hepatocellular carcinoma expression pattern. Pathway enrichment analysis and survival analysis were conducted to evaluate the biological function and prognostic effect of cancer-testis genes. Clustering analysis and coexpression analysis were performed to illustrate cancer-testis gene expression patterns in hepatocellular carcinoma. The association of gene expression of each cancer-testis gene to the corresponding methylation status was detected. Finally, we explored the associations between cancer-testis genes and CD8 + T-cell infiltration in hepatocellular carcinoma by TISIDB, and then validated it in an independent hepatocellular carcinoma cohort with 72 patients. Results: A total of 59 testis-specific genes were identified highly expressed in hepatocellular carcinoma. Pathway enrichment analysis revealed that cancer-testis genes in hepatocellular carcinoma significantly involves in the process of cell cycle regulation. Most of the cancer-testis genes were coexpressed, and cluster analysis suggested that cancer-testis gene expressed in hepatocellular carcinoma is independent of sex, hepatitis status, and histology type. We also found that demethylation might be a regulatory mechanism of cancer-testis gene expression in hepatocellular carcinoma. Survival analysis indicated that cancer-testis genes could predict the prognosis of patients with hepatocellular carcinoma. Furthermore, BUB1B was identified contributing to the resistance of CD8 + T-cell infiltration in hepatocellular carcinoma and was an independent prognostic factor both for overall survival and disease-free survival. Conclusions: Our analysis enables better understanding of cancer-testis genes in hepatocellular carcinoma and provides potential targets for hepatocellular carcinoma treatment. Experimental and clinical studies are needed for further validations.

Expression of cancer-testis antigen in patients with non-small cell lung cancer and its clinical relevance

New progress in immunotherapy of lung cancer

[Expression of Multiple Cancer-Testis Antigen Genes in Non-Small Cell Lung Cancer Treated by Chemotherapy Prior Surgery].

Expression of cancer-testis antigens in the immune microenvironment of non-small cell lung cancer

Aberrant Expression of SCARA5 in Lung Adenocarcinoma and its Clinical Significance

Uncommon/rare oncogenic drivers in non‐small cell lung cancer: Consensus and contention

[Expression of Cancer-Testis Antigens in Human Lung Cancer].

Role of Cancer Testis Antigen in Breast Cancer

A Real-World Observational Study To Explore Clinical Characteristics Of Chinese Patients With T1 Non-Small Cell Lung Cancer Complicated With Lymph Metastases.

Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment

Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients

Cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets

Expressions of the Genes Related to Chemotherapeutic Sensitivity in Non-Small Cell Lung Cancer and Their Correlation to Its Clinical Pathology

Cancer-Testis Gene Expression in Hepatocellular Carcinoma: Identification of Prognostic Markers and Potential Targets for Immunotherapy

Current status of immunotherapy for non-small cell lung cancer

A panel of cancer testis antigens in pan squamous cell carcinomas: implication for biomarkers and therapeutic targets

The value of lung function assessment and Testin expression detection in clinicopathological features and prognosis of NSCLC patients

Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer

Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing

Cancer testis antigen burden (CTAB): a novel biomarker of tumor-associated antigens in lung cancer

The Expressions and Clinical Significance of P53, C-erbB-2 and VEGF in Non-Small Cell Lung Cancer